Katrina Pedersen

Medicine & Life Sciences

1. Rectal Neoplasms 100%
2. Adenocarcinoma 95%
3. Pancreatic Neoplasms 81%
4. Neoadjuvant Therapy 47%
5. gemcitabine 45%
6. pembrolizumab 43%
7. Radiotherapy 40%
8. Colorectal Neoplasms 38%
9. Survival 35%
10. 130-nm albumin-bound paclitaxel 35%
11. Neoplasms 33%
12. Drug Therapy 32%
13. regorafenib 32%
14. Progression-Free Survival 26%
15. Radiation 25%
16. Margins of Excision 24%
17. Confidence Intervals 24%
18. Therapeutics 22%
19. ulixertinib 22%
20. 4-fluorobenzoyl-TN-14003 22%
21. tosedostat 22%
22. defactinib 21%
23. 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 20%
24. Clobetasol 20%
25. Colonic Neoplasms 19%
26. tremelimumab 18%
27. Guidelines 18%
28. durvalumab 17%
29. Consolidation Chemotherapy 16%
30. tanespimycin 15%
31. Colony-Stimulating Factor Receptors 15%
32. Prior Authorization 15%
33. Circulating Tumor DNA 14%
34. Gastrointestinal Neoplasms 14%
35. Safety 14%
36. CXCR4 Receptors 14%
37. Platelet-Derived Growth Factor Receptors 13%
38. T-Lymphocytes 13%
39. Capecitabine 12%
40. Everolimus 12%
41. Macrophage Colony-Stimulating Factor 12%
42. Vascular Endothelial Growth Factor Receptor 12%
43. Non-Randomized Controlled Trials 11%
44. Psychology Rejection 11%
45. Quality-Adjusted Life Years 11%
46. Genetic Counseling 11%
47. Non-alcoholic Fatty Liver Disease 11%
48. DNA Methylation 10%
49. HSP90 Heat-Shock Proteins 9%
50. African Americans 9%